Browse
Submit Data
Databases
API
Help

Dataset Information

36 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer

ABSTRACT: Phase I/II, Open-labeled, Prospective, Multi-center study of a Pretargeted Radioimmunotherapy in metastatic colorectal cancer with ractionated injections of TF2 plus 90Y-IMP288 (RITCOLON).

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2179049 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer

Project description:This study is being done to select an appropriate TF2 bsMAb dose suitable for pretargeting the 111In/90Y-labeled hapten-peptide (IMP-288). Eligible patients will receive a fixed dose of 90Y-IMP-288 4 days after the TF2 antibody injection. Two different dose levels of TF2 will be studied in the first part. Once an appropriate TF2 dose is selected based on information learned from the first 2 dose levels, patients will be enrolled onto several different increasing dose levels of 90Y-IMP-288.

| 2100560 | ecrin-mdr-crc

Advanced Age is Associated with Worsened Outcomes and a Unique Genomic Response in Severely Injured Patients with Hemorrhagic Shock

Project description:We performed epidemiological, cytokine, and transcriptomic analyses on a prospective, multi-center cohort of 1,928 severely injured patients.

2015-01-06 | GSE64711 | GEO

Comparative transcriptomics of Aspergillus niger when deleted or overexpressed for the putative transcription factors MjkA, MjkB and the histon deactelyase HdaX

Project description:Purpose: Expression profiling of two ORFs encoding putative transcription factors: An07g07370 (TF1/MjkA) and An12g07690 (TF2/MjkB), and a histone deacetylase (An09g06520, HdaX) under carbon-limited batch cultivations (biological duplicate runs) in Aspergillus niger. Methods: Single deletion strains for TF1, TF2 and HD, respectively, (ii) a double deletion strain for TF1 and TF2, and (iii) individual conditional overexpression mutants for TF1, TF2 and HD using the Tet-on system were analysed. Samples were taken at exponential and post-exponential growth phase (technical duplicate) and analysed by RNA-Seq analysis (DOI).

2018-11-07 | GSE119311 | GEO

RNA sequensing data of a phase 2 clinical trial of pancreatic ductal adenocarcinoma treated with entinostat in combination with nivolumab

Project description:We conducted a single-center, open-label, Simon two-stage, phase II study of entinostat in combination with the PD1 inhibitor nivolumab in patients with advanced pancreatic ductal adenocarcinoma. Patients received oral entinostat 5 mg once a week. After a 14-day lead-in with entinostat monotherapy, patients concurrently receive entinostat 5 mg orally once a week plus nivolumab 240 mg intravenously until the time of progression or unacceptable toxicities.

2024-07-29 | GSE248014 | GEO

Advanced Age is Associated with Worsened Outcomes and a Unique Genomic Response in Severely Injured Patients with Hemorrhagic Shock

Project description:We performed epidemiological, cytokine, and transcriptomic analyses on a prospective, multi-center cohort of 1,928 severely injured patients. We wished to characterize the relationship of advanced age to clinical outcomes and to transcriptomic responses after severe blunt traumatic injury with hemorrhagic shock.

2015-01-06 | E-GEOD-64711 | biostudies-arrayexpress

Homo sapiens

Project description:International Multi-Center ADHD Genetics: IMAGE II

| PRJNA80261 | ENA

International Multi-Center ADHD Genetics: IMAGE II

Project description:International Multi-Center ADHD Genetics: IMAGE II

| PRJNA80259 | ENA

Whole Blood Cell Gene Expression Profiling in Patients with Coronary Artery Disease from the PREDICT Trial

Project description:Expression profiling of whole blood cells isolated from patients piror to undergoing cardiac catheterization. PREDICT is a prospective, multi-center coronary catheter-lab trial being run in the US for the purpose of identifying biomarkers associated with coronary disease. A summary of the trial can be found at http://clinicaltrials.gov (identifier # NCT00500617).

2011-03-01 | GSE20681 | GEO

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Project description:This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).

| 2213684 | ecrin-mdr-crc

Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer

Project description:Prospective, open label, multi-dose, sequential dose escalation, single-center, Phase 1 trial

| 66323 | ecrin-mdr-crc